Cardiac Marker Testing Market Size & Share Report, 2023–2032

Cardiac Marker Testing Market - By Product (Consumables, Analyzers), By Biomarker Type (Troponins, Myoglobin, Creatine kinase), By Application (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), By Distribution Channel, By End-use & Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Industry coverage

1.2&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.6&nbsp;&nbsp;&nbsp; Data validation

1.7&nbsp;&nbsp;&nbsp; Data Sources

1.7.1&nbsp;&nbsp;&nbsp; Primary

1.7.2&nbsp;&nbsp;&nbsp; Secondary

1.7.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.7.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Cardiac marker testing industry 360&ordm; synopsis, 2018 &ndash; 2032

2.2&nbsp;&nbsp;&nbsp; Business trends

2.3&nbsp;&nbsp;&nbsp; Regional trends

2.4&nbsp;&nbsp;&nbsp; Product trends

2.5&nbsp;&nbsp;&nbsp; Biomarker type trends

2.6&nbsp;&nbsp;&nbsp; Application trends

2.7&nbsp;&nbsp;&nbsp; Distribution channel trends

2.8&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing prevalence of cardiovascular diseases

3.2.1.2&nbsp;&nbsp;&nbsp;Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing funding from public and private organizations for R&amp;D

3.2.1.4&nbsp;&nbsp;&nbsp;Rising demand for point-of-care (POC) testing

3.2.1.5&nbsp;&nbsp;&nbsp;Increasing government initiatives for the diagnosis of cardiac diseases

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Stringent regulatory frameworks

3.2.2.2&nbsp;&nbsp;&nbsp;Lack of skilled professionals

3.2.2.3&nbsp;&nbsp;&nbsp;Availability of substitute product

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By product

3.3.2&nbsp;&nbsp;&nbsp; By biomarker type

3.3.3&nbsp;&nbsp;&nbsp; By application

3.3.4&nbsp;&nbsp;&nbsp; By distribution channel

3.3.5&nbsp;&nbsp;&nbsp; By end use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Pricing analysis, 2022

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Technology landscape

3.8&nbsp;&nbsp;&nbsp; Future market trends

3.9&nbsp;&nbsp;&nbsp; Gap analysis

3.10&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.11&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Vendor matrix analysis

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By Product (USD Million &amp; Units)

5.1&nbsp;&nbsp;&nbsp; Key trends, by product

5.2&nbsp;&nbsp;&nbsp; Consumables

5.3&nbsp;&nbsp;&nbsp; Analyzers

Chapter 6&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By Biomarker Type (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by biomarker type

6.2&nbsp;&nbsp;&nbsp; Troponins

6.3&nbsp;&nbsp;&nbsp; Myoglobin

6.4&nbsp;&nbsp;&nbsp; Creatine kinase (CK-MB)

6.5&nbsp;&nbsp;&nbsp; Brain natriuretic peptide (BNP)

6.6&nbsp;&nbsp;&nbsp; Ischemia modified albumin (IMA)

6.7&nbsp;&nbsp;&nbsp; Others

Chapter 7&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By Application (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by application

7.2&nbsp;&nbsp;&nbsp; Myocardial infarction

7.3&nbsp;&nbsp;&nbsp; Congestive heart failure

7.4&nbsp;&nbsp;&nbsp; Acute coronary syndrome

7.5&nbsp;&nbsp;&nbsp; Atherosclerosis

7.6&nbsp;&nbsp;&nbsp; Others

Chapter 8&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By Distribution Channel (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp; Brick &amp; mortar

8.4&nbsp;&nbsp;&nbsp; E-commerce

Chapter 9&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By End-use (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

9.2&nbsp;&nbsp;&nbsp; Hospitals

9.3&nbsp;&nbsp;&nbsp; Diagnostic centers

9.4&nbsp;&nbsp;&nbsp; Others

Chapter 10&nbsp;&nbsp;&nbsp;Cardiac Marker Testing Market Size and Forecast, By Region (USD Million)

10.1&nbsp;&nbsp;&nbsp; Key trends, by region

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Germany

10.3.2&nbsp;&nbsp;&nbsp; UK

10.3.3&nbsp;&nbsp;&nbsp; France

10.3.4&nbsp;&nbsp;&nbsp; Spain

10.3.5&nbsp;&nbsp;&nbsp; Italy

10.3.6&nbsp;&nbsp;&nbsp; Poland

10.3.7&nbsp;&nbsp;&nbsp; Sweden

10.3.8&nbsp;&nbsp;&nbsp; The Netherlands

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; Japan

10.4.2&nbsp;&nbsp;&nbsp; China

10.4.3&nbsp;&nbsp;&nbsp; India

10.4.4&nbsp;&nbsp;&nbsp; Australia

10.4.5&nbsp;&nbsp;&nbsp; South Korea

10.4.6&nbsp;&nbsp;&nbsp; Thailand

10.4.7&nbsp;&nbsp;&nbsp; Indonesia

10.4.8&nbsp;&nbsp;&nbsp; Philippines

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Mexico

10.5.3&nbsp;&nbsp;&nbsp; Argentina

10.5.4&nbsp;&nbsp;&nbsp; Columbia

10.5.5&nbsp;&nbsp;&nbsp; Chile

10.5.6&nbsp;&nbsp;&nbsp; Peru

10.6&nbsp;&nbsp;&nbsp; MEA

10.6.1&nbsp;&nbsp;&nbsp; South Africa

10.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp; UAE

10.6.4&nbsp;&nbsp;&nbsp; Israel

10.6.5&nbsp;&nbsp;&nbsp; Turkey

10.6.6&nbsp;&nbsp;&nbsp; Iran

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; Abbott

11.2&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

11.3&nbsp;&nbsp;&nbsp; Biom&eacute;rieux SA

11.4&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories, Inc.

11.5&nbsp;&nbsp;&nbsp; Creative Diagnostics

11.6&nbsp;&nbsp;&nbsp; Danaher Corporation

11.7&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

11.8&nbsp;&nbsp;&nbsp; Life Diagnostics

11.9&nbsp;&nbsp;&nbsp; Perkin Elmer Inc.

11.10&nbsp;&nbsp;&nbsp; Quidel Corporation

11.11&nbsp;&nbsp;&nbsp; Randox Laboratories Ltd.

11.12&nbsp;&nbsp;&nbsp; Siemens Healthineers

11.13&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific 
&nbsp;

Cardiac Marker Testing Market

Get a free sample of this report